AbbVie was founded in 2013 and is headquartered in North Chicago, US

Chairman of the Board and Chief Executive Officer

AbbVie has an office in North Chicago

North Chicago, US (HQ)

1 Waukegan Rd

AbbVie's revenue was reported to be $25.6 b in FY, 2016 which is a **12% increase** from the previous period.

USD

## Revenue (FY, 2016) | 25.6 b |

## Revenue growth (FY, 2015 - FY, 2016), % | 12% |

## Gross profit (FY, 2016) | 19.8 b |

## Gross profit margin (FY, 2016), % | 77% |

## Net income (FY, 2016) | 6 b |

## Market capitalization (28-Jun-2017) | 116.1 b |

## Closing share price (28-Jun-2017) | 72.4 |

## Cash (31-Dec-2016) | 5.1 b |

## EV | 147.8 b |

AbbVie's current market capitalization is $116.1 b.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 18.8 b | 20 b | 22.9 b | 25.6 b |

## Revenue growth, % | 6% | 15% | 12% | |

## Cost of goods sold | 4.6 b | 4.4 b | 4.5 b | 5.8 b |

## Gross profit | 14.2 b | 15.5 b | 18.4 b | 19.8 b |

## Gross profit Margin, % | 76% | 78% | 80% | 77% |

## Operating expense total | 13.1 b | 16.5 b | 15.3 b | 16.3 b |

## Interest expense | (278 m) | (391 m) | (686 m) | (965 m) |

## Income tax expense | 1.2 b | 595 m | 1.5 b | 1.9 b |

## Net Income | 4.1 b | 1.8 b | 5.1 b | 6 b |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 9.6 b | 8.3 b | 8.4 b | 5.1 b |

## Accounts Receivable | 3.9 b | 3.7 b | 4.7 b | 4.8 b |

## Inventories | 1.2 b | 1.1 b | 1.7 b | 1.4 b |

## Current Assets | 17.8 b | 16.1 b | 16.3 b | 16.2 b |

## PP&E | 2.3 b | 2.5 b | 2.6 b | 2.6 b |

## Goodwill | 6.3 b | 5.9 b | 13.2 b | 15.4 b |

## Total Assets | 29.2 b | 27.5 b | 53.1 b | 66.1 b |

## Total Debt | 3.9 b | 4.3 b | 29.6 b | 36.8 b |

## Current Liabilities | 6.9 b | 11.4 b | 10.9 b | 9.8 b |

## Additional Paid-in Capital | 3.7 b | 4.2 b | 13.1 b | 13.7 b |

## Retained Earnings | 1.6 b | 535 m | 2.2 b | 4.4 b |

## Total Equity | 4.5 b | 1.7 b | 3.9 b | 4.6 b |

## Debt to Equity Ratio | 0.9 x | 2.4 x | 7.5 x | 7.9 x |

## Debt to Assets Ratio | 0.1 x | 0.2 x | 0.6 x | 0.6 x |

## Financial Leverage | 6.5 x | 15.8 x | 13.4 x | 14.3 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 4.1 b | 1.8 b | 5.1 b | 6 b |

## Accounts Receivable | 681 m | (172 m) | (1.1 b) | (71 m) |

## Inventories | (56 m) | (203 m) | (434 m) | (38 m) |

## Accounts Payable | (426 m) | (193 m) | 1.5 b | (1.2 b) |

## Cash From Operating Activities | 6.3 b | 3.5 b | 7.5 b | 7 b |

## Cash From Investing Activities | 879 m | (926 m) | (12.9 b) | (6.1 b) |

## Short-term Borrowings | (601 m) | 12 m | (19 m) | (29 m) |

## Dividends Paid | (2.6 b) | (2.7 b) | (3.3 b) | (3.7 b) |

## Cash From Financing Activities | (3.4 b) | (3.3 b) | 5.8 b | (3.9 b) |

## Income Taxes Paid | 1.3 b | 498 m | 1.1 b | 3.6 b |

USD | Y, 2016 |
---|---|

## EV/CFO | 21 x |

## Revenue/Employee | 1 m |

## Debt/Equity | 7.9 x |

## Debt/Assets | 0.6 x |

## Financial Leverage | 14.3 x |

Source: 442 public H-1B filings from AbbVie